Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups: FLOW Trial Post Hoc Analyses
In brief
FLOW analysis finds no evidence semaglutide effects differ by race or ethnicity
In a post hoc analysis of 3,533 people with chronic kidney disease and type 2 diabetes, semaglutide's effects on kidney outcomes, major cardiovascular events, and death did not differ significantly between Black and non-Black participants or Hispanic and non-Hispanic participants over a median 3.4 years. The analysis is exploratory and cannot prove equal effects, particularly given the small number of Black participants.
- Journal
- Clinical journal of the American Society of Nephrology : CJASN (Q1)
- Published
- 18 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Carlos Campos, Richard Pratley, Sherif Mehanna, Caroline Swift, Søren Rasmussen, Peter Rossing, et al.
- PMID
- 43050287
- DOI
- 10.2215/CJN.0000001242
Why clinicians should know about it
- Picked for Nephrology (paper of the day, 22 November 2026): FLOW trial analysis addresses semaglutide kidney outcomes across patient subgroups
Abstract
BACKGROUND: Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups. METHODS: Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity. RESULTS: Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05). CONCLUSION: In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.